Roche and Discuva partner to combat drug-resistant infections

03/1/2014 | Genetic Engineering & Biotechnology News

Roche Holding and Discuva have entered a licensing partnership to discover and develop antibiotics to treat infections caused by multidrug-resistant Gram-negative bacteria using Discuva's SATIN technology platform. Under the agreement, Discuva will receive $16 million upfront and up to $175 million for every product developed as well as royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY